EDITORIAL SECTIONS

Professor Mads Hald Andersen, DMSc, DScTech, PhD, is Director of the National Center for Cancer Immune Therapy, CCIT-DK, at Copenhagen University Hospital Herlev, Denmark. He discovered tumor microenvironment antigens and anti-regulatory T cells and defined their role in immune regulation. He initiated the immune modulatory vaccine concept and has authored more than 250 publications and 25 patents.

Elodie Decuypere received her Ph.D in Organic Synthesis from the University of Paris-Saclay with specialization in Click Chemistry. After her Ph.D, Elodie specialized in oligonucleotide chemistry with her two postdoc in ETH Zürich and Roche Basel. In 2020, Elodie joined Bachem as a Specialist Marketing and works on the creation of scientific content for marketing materials.

Giuseppe Maruccio is Full Professor at Department of Mathematics and Physics – University of Salento and head of Omnics Research Group which comprises researchers with different backgrounds from physics to life sciences working in cross-disciplinary areas  with applications from -onics (electronics, spintronics and magnonics) to -omics technologies (genomics, proteomics and cellomics)

Anna Grazia Monteduro is researcher at Department of Mathematics and Physics - University of Salento in Lecce (Italy) and carries out her research activity within Omnics Research Group in the fields of (i) sensors, lab on chip and organ on chip; (ii) Nanoelectronics, spintronics, nanomagnetism and applied superconductivity.

Silvia Rizzato is researcher at the Department of Mathematics and Physics - University of Salento and carries out her research activity within Omnics Research Group on the development of new devices and processes for sensing and spintronics, including surface acoustic waves devices, electrochemical sensors and colloidal lithography for LSPR sensors.

Giusi Caragnano is a PhD student in Nanotechnologies at the University of Salento - CNR Nanotec and she is part of the Omnics Research Group. Her research activity concerns development of the Organ-on-chip to support the treatment of both chronic and cancerous gastrointestinal diseases

Dr Reuben Carr has over 25 years of experience in developing proprietary biocatalytic processes for fine chemical and pharmaceutical manufacturing. He specialises in using directed evolution to engineer natural enzymes to carry out novel chemical reactions, enabling the synthesis of challenging molecular targets for clients and customers.

Researcher, Donghua University